Omacetaxine in Gleevec-resistant CML therapy continues to impress

Submitted by Ross Bonander Sun 12/06/2009

Share on Tumblr

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

According to the results of a small study presented at the American Society of Hematology meeting this weekend, omacetaxine, the investigational drug under development by ChemGenex Pharmaceuticals Limited to treat patients with T315I-positive chronic myeloid leukemia, continues to improve upon its safety profile and efficacy.

Although Gleevec is first-line therapy for chronic myeloid leukemia, some patients have a genetic mutation (T315I) that makes them Gleevec-resistant. Researchers at ChemGenex believe that omacetaxine holds great promise for these patients.

Although currently only used to treat leukemia in China and not approved in Europe or the US, the FDA recently fast-tracked omacetaxine.

Presented as an abstract, until published in a peer-reviewed journal the conclusions of this study are considered preliminary only.

By Ross Bonander

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Support Groups

SupportGroups.com

For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Cancer Support Groups

Find a Treatment Facility Near You

Click on a state below to find Lymphoma treatment options that could be right for you.

Select a State Below

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.